Thematics Asset Management Acquires 6,599 Shares of Eli Lilly and Company $LLY

Key Points

• Thematics Asset Management significantly increased its stake in Eli Lilly by 4,999.2%, acquiring 6,599 shares, bringing its total holdings to 6,731 shares valued at approximately $5.56 million.
• CEO David A. Ricks and Director J Erik Fyrwald both made recent insider purchases of Eli Lilly shares, indicating confidence in the company's future performance.
• Despite recent downgrades from some analysts, Eli Lilly maintains a consensus rating of "Moderate Buy" with an average price target of $950.17.

Thematics Asset Management increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 4,999.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,731 shares of the company's stock after acquiring an additional 6,599 shares during the period. Thematics Asset Management's holdings in Eli Lilly and Company were worth $5,559,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the business. Redwood Investments LLC boosted its position in Eli Lilly and Company by 0.5% in the 4th quarter. Redwood Investments LLC now owns 2,209 shares of the company's stock valued at $1,705,000 after buying an additional 12 shares during the last quarter. Hobbs Wealth Management LLC boosted its position in Eli Lilly and Company by 0.8% in the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock valued at $1,205,000 after buying an additional 12 shares during the last quarter. Hixon Zuercher LLC boosted its position in Eli Lilly and Company by 0.7% in the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock valued at $1,477,000 after buying an additional 12 shares during the last quarter. O Brien Wealth Partners LLC boosted its position in Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after buying an additional 12 shares during the last quarter. Finally, Ascent Capital Management LLC boosted its position in Eli Lilly and Company by 2.5% in the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock valued at $409,000 after buying an additional 12 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CEO David A. Ricks purchased 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director J Erik Fyrwald acquired 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the acquisition, the director owned 74,578 shares of the company's stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased a total of 4,514 shares of company stock valued at $2,894,841 in the last three months. Corporate insiders own 0.13% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have commented on the company. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their price objective for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. Daiwa America downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Wall Street Zen raised Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research note on Friday. Hsbc Global Res downgraded Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. Finally, Guggenheim cut their price target on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $950.17.

Eli Lilly and Company Stock Performance

LLY opened at $710.7290 on Friday. The business's 50-day moving average price is $754.70 and its two-hundred day moving average price is $790.53. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $972.48. The company has a market capitalization of $672.67 billion, a price-to-earnings ratio of 46.45, a P/E/G ratio of 0.99 and a beta of 0.44. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter last year, the company earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 39.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.